To Evaluate And Compare The Visual And Refractive Outcome Of Eyecryl And Evo/Evo+ Icl
Published 2025 - 43rd Congress of the ESCRS
Reference: PO741 | Type: Free paper | DOI: 10.82333/28cz-4z62
Authors: Esin Sogutlu Sarı* 1 , Shola Hasanova 2
1Bursa Uludag University,BURSA,Türkiye, 2Doruk Saglik Grubu,BURSA,Türkiye;Bursa Uludag University,BURSA,Türkiye
Purpose
To evaluate and compare the visual and refractive outcome after implantation of Eyecryl, a hydrophilic acrylic phakic intraocular lens implant from Biotech Vision Care (EP IOL) in moderate to high myopia and astigmatism with an established method using Visian Implantable Collamer Lenses (EVO/EVO+ latest model of ICL, STAAR Surgical Company).
Setting
Department Of Ophthalmology at Dr Rajendra Prasad Centre for Ophthalmic sciences, AIIMS, New Delhi
Methods
This Non-Randomised Prospective, Longitudinal interventional study included patients with high myopia and myopic astigmatism who underwent either Eyecryl pIOL or ICL (EVO/EVO +) lens implantation in either one or both eyes. Both the lenses were compared for 6 months to assess the visual, refractive outcome, rotational stability and changes in the ocular parameters and adverse events after implantation.
Results
A total of 82 patients (164 eyes) were enrolled of which Group 1 of 41 patients (82 eyes) recieved EP IOL and Group 2 of 41 patients (82 eyes) recieved ICL implantation. Preoperative mean ± standard deviation of spherical equivalent (SE) and cylinder was -9.17
± 4.20 and 1.32 ± 1.04 diopters (D) in Group 1 and -8.53 ± 4.71 and -1.17 ± 0.99 D in Group 2, respectively. At 6 months of follow-up, there was no significant difference between the mean
uncorrected distance visual acuity, corrected distance visual acuity, spherical equivalent, and residual astigmatism between the two groups (P > 0.05 for all parameters)
Conclusions
Both the phakic IOLs showed comparable outcomes in safety, stability and effectively correcting high myopia and myopic astigmatism at 1 month, 3 months and 6 months postoperatively.